Lipocine Inc. Files 8-K for Financials and Exhibits

Ticker: LPCN · Form: 8-K · Filed: 2025-12-11T00:00:00.000Z

Sentiment: neutral

Topics: 8-k, financials, exhibits

Related Tickers: LPCN

TL;DR

LPCN filed an 8-K on 12/11 for 12/8 events - mostly financials/exhibits.

AI Summary

Lipocine Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates Lipocine Inc. is providing updated financial information and exhibits to the SEC, which is standard procedure but important for investors to review for company health.

Risk Assessment

Risk Level: low — This is a routine filing for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The provided text states the filing concerns 'Financial Statements and Exhibits' but does not list the specific documents included.

Are there any material events reported in this 8-K beyond the standard financial disclosures?

The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' with no specific material events detailed in the excerpt.

When was the earliest event reported in this 8-K?

The earliest event reported in this 8-K was on December 8, 2025.

What is Lipocine Inc.'s principal executive office address?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the SEC file number for Lipocine Inc.?

Lipocine Inc.'s SEC file number is 001-36357.

From the Filing

0001493152-25-027273.txt : 20251211 0001493152-25-027273.hdr.sgml : 20251211 20251211170125 ACCESSION NUMBER: 0001493152-25-027273 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20251208 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251211 DATE AS OF CHANGE: 20251211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 251565664 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm 8-K false 0001535955 0001535955 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): December 8, 2025     LIPOCINE INC.   (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events.   The Company presented posters for LPCN 2101 at the American Epilepsy Society (AES) Annual Meeting held December 5 th through the 9 th , 2025 in Atlanta, GA. The posters are furnished as Exhibit 99.1 and 99.2 to this report and incorporated by reference herein.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description 99.1   Poster entitled “Clinical Pharmacokinetics and Tolerabilit

View on Read The Filing